Novartis AG — Director's Dealing 2018

Mar 28, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2018-03-27

Reporting Person: Novartis Institutes for BioMedical Research, Inc. (10% Owner)
Reporting Person: NOVARTIS AG (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Preferred Stock	$		Common Stock (1979226)		Direct

Footnotes

F1: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2: The securities reported herein are held of record by Novartis Institutes for BioMedical Research, Inc. ("NIBRI"). NIBRI is an indirect wholly-owned subsidiary of Novartis AG. Novartis AG may therefore be deemed to have or share beneficial ownership of the Series B Preferred Stock held directly by NIBRI.